FDA approves Jazz's Ziihera for first-line treatment of HER2-positive gastroesophageal cancer

JAZZ Jazz Pharmaceuticals plc

$218.42 -1.81%

View chart & analysis →

ZYME +2.10% RVMD +0.87%

1. 1The FDA approved two Ziihera combination regimens from Jazz Pharmaceuticals (JAZZ) as first-line therapy for adults with advanced HER2-positive gastroesophageal cancer
2. 2The approvals cover chemotherapy combinations and a combination with BeiGene's (ONC) Tevimbra, with Jazz paying Zymeworks (ZYME) a $250 million milestone payment
3. 3In the Phase 3 HERIZON-GEA-01 trial, the regimen reduced the risk of disease progression by 35% and the risk of death by 28%; Jazz shares rose about 4% on Tuesday to a record high

Source Stocktwits +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →